Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue
January 7, 2021
News
Active Biotech publishes prospectus and certain new financial information included in the prospectus
January 5, 2021
Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue
November 30, 2020
Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma
August 3, 2020
New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting
November 5, 2019
Active Biotech has entered into an agreement regarding sale of the Company’s property – extraordinary general meeting on April 4, 2019
March 13, 2019
Active Biotech has received an indicative bid for the property in Lund – the Board is positive
February 1, 2019
Active Biotech provides updated information about the company’s financial position
December 10, 2018
New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference HSG 2018
November 8, 2018
<\span>
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”
September 13, 2018